Wall Street Experts
ver. ZuMIgo(08/25)
Prognozy (mln) dla Luye Pharma Group Ltd.
| Okres |
2023-12-31 |
2024-12-31 |
2025-12-31 |
2026-12-31 |
| Przychód (średnia) |
6,143.08 |
6,830.64 |
7,811.02 |
8,858.84 |
| Przychód Δ r/r |
0.00% |
11.19% |
14.35% |
13.41% |
| Przychód (min) |
5,917.52 |
6,673.31 |
7,386.02 |
8,508.67 |
| Przychód (max) |
6,350.74 |
6,987.97 |
8,236.02 |
9,209.00 |
| EBITDA (średnia) |
2,485.55 |
2,759.66 |
2,407.39 |
2,730.34 |
| EBIT (średnia) |
2,596.44 |
2,882.78 |
1,626.06 |
1,844.19 |
| EBIT % |
42.27% |
42.20% |
20.82% |
20.82% |
| Zysk netto (średni) |
532.61 |
676.53 |
964.88 |
1,189.12 |
| Zysk netto % |
8.67% |
9.90% |
12.35% |
13.42% |
| EPS (średnia) |
0.13 |
0.16 |
0.21 |
0.26 |
| Liczba analityków (Przychody) |
3 |
3 |
3 |
4 |
| Liczba analityków (EPS) |
3 |
2 |
2 |
3 |
| symbol |
2186.HK |
2186.HK |
2186.HK |
2186.HK |